What were Alivus Life Sciences Ltd's latest quarterly results?
Alivus Life Sciences Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +14.8%
- Revenue Growth YoY: +6.0%
- Operating Margin: 31.0%
Alivus Life Sciences Ltd: Stock Analysis & Fundamentals
Updated this weekAlivus Life Sciences Ltd (Pharmaceuticals Bulk Drugs & Formulation) — fundamental analysis, earnings data, and key metrics. PE: 23.3. ROE: 19.0%. This stock is not currently in the Nifty 500 momentum outperformers list.
Alivus Life Sciences Ltd Key Facts
What's Happening
🌐FII stake decreased 1.0% this quarter
🏛️DII accumulation — stake up 1.3%
Key Numbers
Current Price
₹1,108
Dividend Yield
0.45%
Market Cap
13.6K Cr
Valuation
N/AOther Top Pharmaceuticals Bulk Drugs & Formulation Stocks Beating Nifty 500
Frequently Asked Questions: Alivus Life Sciences Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Alivus Life Sciences Ltd's current PE ratio?
Alivus Life Sciences Ltd's current PE ratio is 23.3x.
- Current PE: 23.3x
- Market Cap: 13.6K Cr
- Dividend Yield: 0.45%
What is Alivus Life Sciences Ltd's price-to-book ratio?
Alivus Life Sciences Ltd's price-to-book ratio is 4.1x.
- Price-to-Book (P/B): 4.1x
- Book Value per Share: ₹271
- Current Price: ₹1108
Is Alivus Life Sciences Ltd a fundamentally strong company?
Alivus Life Sciences Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 25.0%
Is Alivus Life Sciences Ltd debt free?
Alivus Life Sciences Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹57 Cr
What is Alivus Life Sciences Ltd's return on equity (ROE) and ROCE?
Alivus Life Sciences Ltd's return ratios over recent years
- FY2024: ROCE 28.0%
- FY2025: ROCE 25.0%
- FY2026: ROCE 25.0%
Is Alivus Life Sciences Ltd's cash flow positive?
Alivus Life Sciences Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹565 Cr
- Free Cash Flow (FCF): ₹-5 Cr
- CFO/PAT Ratio: 100% (strong cash conversion)
What is Alivus Life Sciences Ltd's dividend yield?
Alivus Life Sciences Ltd's current dividend yield is 0.45%.
- Dividend Yield: 0.45%
- Current Price: ₹1108
Who holds Alivus Life Sciences Ltd shares — promoters, FII, DII?
Alivus Life Sciences Ltd's shareholding pattern (Mar 2026)
- Promoters: 74.9%
- FII (Foreign): 5.3%
- DII (Domestic): 7.3%
- Public: 12.6%
Is promoter holding increasing or decreasing in Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 74.9% (Mar 2026)
- Previous Quarter: 74.9% (Dec 2025)
- Change: -0.04% (decreasing — worth monitoring)
Is Alivus Life Sciences Ltd a new momentum entry or an established outperformer?
Alivus Life Sciences Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Alivus Life Sciences Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Alivus Life Sciences Ltd may be worth studying
- Cash flow is positive — CFO ₹565 Cr
What is the investment thesis for Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd investment thesis summary:
What is the future outlook for Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.